<div id="readability-page-1"><p>Ausdal Financial Partners Inc. bought a new stake in shares of  Exact Sciences Corporation (NASDAQ:EXAS - Free Report) in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The institutional investor  bought 90,988 shares of the medical research company's stock, valued at approximately $4,978,000.</p><div><p><span></span><span>Get <strong>Exact Sciences</strong> alerts:</span></p></div><ul><li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li></ul><p>Several other institutional investors have also added to or reduced their stakes in EXAS. Westside Investment Management Inc. raised its position in  Exact Sciences by 100.0% in the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company's stock worth $31,000 after acquiring an additional 271 shares during the period.  Country Trust Bank bought a new stake in shares of  Exact Sciences during the 2nd quarter valued at $32,000.  Quent Capital LLC purchased a new stake in shares of  Exact Sciences in the 3rd quarter worth $48,000.  OFI Invest Asset Management increased its stake in shares of  Exact Sciences by 241.2% in the 3rd quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company's stock worth $59,000 after purchasing an additional 767 shares in the last quarter.  Finally, Parallel Advisors LLC raised its holdings in  Exact Sciences by 47.6% in the 3rd quarter. Parallel Advisors LLC now owns 1,179 shares of the medical research company's stock worth $65,000 after purchasing an additional 380 shares during the period. 88.82% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several research firms recently weighed in on EXAS. William Blair downgraded Exact Sciences from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday, November 20th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Exact Sciences in a research note on Thursday, January 22nd. Evercore  set a $105.00 price objective on Exact Sciences and gave the company an &#34;in-line&#34; rating in a research report on Monday, January 5th. Wells Fargo &amp; Company  reiterated an &#34;equal weight&#34; rating and set a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Finally, Barclays  reissued an &#34;equal weight&#34; rating and issued a $105.00 target price (up from $77.00) on shares of Exact Sciences in a report on Thursday, November 20th. Twenty-one analysts have rated the stock with a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Reduce&#34; and an average price target of $92.13.</p><ul><li>3 Hot Stocks Bought by Members of Congress: Follow the Money</li></ul><p><b>View Our Latest Stock Report on Exact Sciences</b></p><h2>Exact Sciences Trading Up 0.3%</h2><p>Shares of EXAS opened at $103.57 on Friday. The firm has a market cap of $19.77 billion, a P/E ratio of -94.15, a price-to-earnings-growth ratio of 2.36 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $103.75. The company has a 50 day simple moving average of $102.83 and a two-hundred day simple moving average of $83.86. </p><ul><li>Time to buy these 3 healthcare companies that raised revenue guidance?</li></ul><p>Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same quarter in the previous year, the company posted ($0.06) earnings per share. The firm's revenue was up 23.1% on a year-over-year basis.  On average, equities analysts expect that  Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year. </p><h2>Exact Sciences Profile</h2> (Free Report)<p>Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.  </p><p>Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Exact Sciences</li><li>The gold chart Wall Street is terrified of…</li><li>Elon Musk already made me a “wealthy man”</li><li>Silver paying 20% dividend. Plus 68% share gains</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>A personal warning from Martin Weiss (Please read)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVhBUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Exact Sciences Right Now?</h2><p>Before you consider Exact Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.</p><p>While Exact Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Ausdal Financial Partners Inc. has acquired a new stake in Exact Sciences Corporation, purchasing 90,988 shares valued at approximately $4.98 million. Other institutional investors have also adjusted their positions in EXAS. Analysts have mixed opinions on the stock, with William Blair downgrading it to 'market perform' and Wells Fargo raising its price target to $105. Exact Sciences reported a loss of $0.21 EPS in its latest earnings, missing estimates, but revenue increased by 23.1% year-over-year. The stock is currently trading at $103.57 with a market cap of $19.77 billion.</p>

Market Beat

SPDR S&P Biotech

iShares US Healthcare Providers

Health Care Select Sector SPDR

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Genomics Immunology and Healthcare ETF

Exact Sciences

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Ausdal Financial Partners Inc. Buys New Position in Exact Sciences Corporation $EXAS